The abstract is read at the publisher; the summary is JClub's.
A selective PAP plus universal HepB-BD policy in South Africa is modeled as the most cost-effective option, averting the greatest disease burden at a willingness-to-pay threshold of ZAR 57,281.
- Why it matters: South Africa introduced a selective HepB-BD policy in 2023, but it differs from WHO’s universal birth-dose recommendation, leaving uncertainty about which strategy best balances costs and health benefits.
- What they did: Using a validated hepatitis B transmission and progression model, the study simulated 2025–100 outcomes for current selective PAP plus selective HepB-BD, universal HepB-BD-only, and selective PAP plus universal HepB-BD, compared with no HepB-BD.
- The result: The number needed to vaccinate per vertically acquired chronic hepatitis B infection averted was 6 (95% UI 3–15) under current policy, versus 462 (223–1479) for universal HepB-BD-only and 77 (38–240) for selective PAP plus universal HepB-BD, while the latter still averted the most burden and was most cost-effective.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.